Efficacy and Safety of Aspirin for Prevention of Hepatocellular Carcinoma: An Updated Meta-analysis.

Lun-Jie Yan Sheng-Yu Yao Hai-Chao Li Guang-Xiao Meng Kai-Xuan Liu Zi-Niu Ding Jian-Guo Hong Zhi-Qiang Chen Zhao-Ru Dong Tao Li

Published in: Journal of clinical and translational hepatology (2022)

Our meta-analysis confirmed that use of aspirin significantly reduced the incident risk of HCC. Regular and long-term aspirin use offers a greater advantage. Aspirin use was associated with an increased risk of bleeding. We recommend 100 mg/d aspirin as a feasible dose for further research on primary prevention of HCC in a broad at-risk population.

Keyphrases

low dose
systematic review
cardiovascular events
antiplatelet therapy
meta analyses
anti inflammatory drugs
cardiovascular disease
acute coronary syndrome
coronary artery disease
percutaneous coronary intervention
type diabetes